| Literature DB >> 26321100 |
Brett L Houston1, Rachelle Govia2, Ahmed M Abou-Setta3, Gregory J Reid2, Marie Hadfield2, Chantalle Menard4, Jocelyn Noyd5, Susan Main5, Ryan Zarychanski6.
Abstract
Rh alloimmunization remains a potentially devastating complication of pregnancy, with fetal anemia causing hydrops and intrauterine death. Intrauterine transfusion is the standard treatment, but is particularly dangerous before 20 weeks gestation. When the need for intrauterine transfusion is anticipated early in pregnancy, immune-modulating therapies such as plasmapheresis and IVIG have been used to delay transfusion to a later gestational age. We report a 35-year-old G5P1 Rh(D)-negative woman with severe Rh alloimmunization managed successfully with sequential plasmapheresis, intravenous immune globulin and intrauterine transfusion. The optimal plasmapheresis treatment protocol and incremental benefit of IVIG remains unknown.Entities:
Keywords: Alloimmunization; Hemolytic disease of the fetus and newborn; Intravenous immune globulin; Plasmapheresis; Pregnancy
Mesh:
Substances:
Year: 2015 PMID: 26321100 DOI: 10.1016/j.transci.2015.07.010
Source DB: PubMed Journal: Transfus Apher Sci ISSN: 1473-0502 Impact factor: 1.764